



PATENT

RECEIVED  
AUG 29 2001  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Donald S. Karanewsky et al.  
Application No. : 09/836,442  
Filed : April 16, 2001  
For : (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE  
ICE/ced-3 FAMILY OF CYSTEINE PROTEASES

Art Unit : 1653  
Docket No. : 480140.444D1  
Date : August 24, 2001

Commissioner for Patents  
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns  
Registration No. 33,507

KRH:sfl

Enclosures:

Postcard  
PTO/SB/21  
Form PTO-1449  
Cited References (17)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

D:\NrPortb\iManage\SHANEL\209452\_1.DOC

GAU165-3  
pt#5

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

To be used for all correspondence  
after initial filing)

Application Number	09/836,442
Filing Date	April 16, 2001
First Named Inventor	Donald S. Karanewsky
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket No.	480140.444D1


RECEIVED  
AUG 19 2001  
TECH CENTER 1600  
2001

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> Communication to Group
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> 17 Cited References	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Request for Refund	


## Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Karl R. Hermanns, 33,507	 <b>00500</b> <small>PATENT TRADEMARK OFFICE</small>
Signature		
Date	8/24/01	

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Shane F. Lambing	
Signature		Date: 8/24/01

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480140.444D1	APPLICATION NO. 09/836,442
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS			
		Donald S. Karanewsky et al.		FILING DATE April 16, 2001	

AUG 27 2001

PATENT &amp; TRADEMARK OFFICE #33

## U.S. PATENT DOCUMENTS

*EXAMINER'S INITIAL	TRADEMARK OFFICE #	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,656,627	08/12/97	Bemis et al.	514	221	
	AB	5,714,484	02/03/98	Zimmerman et al.	514	231.5	
	AC	5,919,790	07/06/99	Allen et al.	514	278	
	AD	6,242,422 B1	06/05/01	Karanewsky et al.	514	19	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AE	EP 623 592 B1	06/27/01	EPO		
	AF	EP 623 606 B1	01/07/98	EPO		
	AG	EP 644 197 B1	09/09/98	EPO		
	AH	EP 761 680 A2	03/12/97	EPO		
	AI	GB 2,292,149	02/14/96	UK		
	AJ	WO 93/09135	05/13/93	WIPO		
	AK	WO 95/05192	02/23/95	WIPO		
	AL	WO 96/30395	10/03/96	WIPO		
	AM	WO 97/22618	06/26/97	WIPO		
	AN	WO 99/47545	09/23/99	WIPO		
	AO	WO 99/66945	12/29/99	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AP	Dolle et al., "Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1 $\beta$ -Converting Enzyme Inhibitor," <i>J. Medicinal Chemistry</i> 40(13):1941-1945, June 20, 1997.
AQ	Semple et al., "Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1 $\beta$ -Converting Enzyme (ICE)," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 8(8):959-964, April 21, 1998.

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).